PatentBlurb

examples - [Fed. Cir. finds lip synching animation software eligible under § 101 (posted 05/11/25)]

len (len@undisclosed.example.com) — 2026-04-08T22:29:18+00:00

Eligibility: Example case law Fed. Cir. holds claims to targeted advertising as ineligible (posted 03/07/24} Claim 1. A method of targeting at least one associated advertisement from an Internet search [. . .], comprising: identifying at least one search result item [. . .];(c)

mcro_15-1080_reporter_.pdf - created

len (len@undisclosed.example.com) — 2026-04-08T22:29:15+00:00

amdocs_15-1180_reporter_.pdf - created

len (len@undisclosed.example.com) — 2026-04-03T19:37:03+00:00

2026 - [In re United States]

len (len@undisclosed.example.com) — 2026-04-03T03:11:20+00:00

2026 Federal Circuit Prededential Decisions Prompt For the attached Federal Circuit Opinion: First, identify the most salient issue discussed in the attached Federal Circuit opinion. The most salient issue is either the most novel legal issue, the one that the court spends the most time discussing, or the legal principle upon which the case is decided, or some combination of the three.

2025 - ↷ Page moved and renamed from 2025fc-precedential to precedential:2025

len (len@undisclosed.example.com) — 2026-04-03T00:04:54+00:00

2025 Federal Circuit Patent-Related Precedential Opinions 101 Eligibility Expand [PowerBlock Holdings, Inc. v. iFit Inc.]: Machine is eligible when it is “sufficiently specific” and “consists of parts, or of certain devices and combination of devices.” The Federal Circuit reversed the district court’s dismissal of PowerBlock’s claims under § 101, holding that claims directed to selectorized dumbbells with motorized weight selection were not abstract ideas. The court emphasized that claim 1 …

2025fc-precedential - ↷ Page moved and renamed from 2025fc-precedential to precedential:2025

len (len@undisclosed.example.com) — 2026-04-03T00:04:54+00:00

obviousness - [Factual Basis is required for obviousness (posted 03/30/26)]

len (len@undisclosed.example.com) — 2026-03-30T20:46:47+00:00

Obviousness: Purdue In the 1990s Purdue Pharma developed an extended release formulation of Oxycodone, the active ingredient of OxyContin. In the 2000s, the FDA had become increasingly concerned about toxicity when taken in large quantities. In 2010, Purdue reformulated OxyContin, which the FDA approved.

in_re_warner_reporter_.pdf - removed

len (len@undisclosed.example.com) — 2026-03-30T20:42:49+00:00

in_re_warner_reporter_.pdf - created

len (len@undisclosed.example.com) — 2026-03-30T20:42:26+00:00

blog_list

len (len@undisclosed.example.com) — 2026-03-23T21:24:25+00:00

Major Resources Most of these are blogs, but there are news and educational sites as well. Please see the Disclaimer for information on PatentBlurb's use of these icon images. Abbrev. Name URL http://promotetheprogress.com/blog/ http://www.krajec.com/index.php?/weblog/archives/ http://alleylegal.co…

phillips_v_awh_corp.pdf - created

len (len@undisclosed.example.com) — 2026-03-02T14:54:20+00:00

smeds-corps.pdf - created

len (len@undisclosed.example.com) — 2026-02-09T17:29:08+00:00

smeds-applicants-practitioners.pdf - created

len (len@undisclosed.example.com) — 2026-02-09T17:23:17+00:00

in_re_kahn_reporter_.pdf - created

len (len@undisclosed.example.com) — 2026-01-19T19:45:31+00:00

in_re_kahn_reporter_.pdf - created

len (len@undisclosed.example.com) — 2026-01-19T19:44:36+00:00

igt_23-2262.pdf - created

len (len@undisclosed.example.com) — 2026-01-17T23:46:15+00:00

iqris_23-2062.pdf - created

len (len@undisclosed.example.com) — 2026-01-17T23:32:51+00:00

eye_therapies_23-2173.pdf - created

len (len@undisclosed.example.com) — 2026-01-12T05:16:50+00:00

colibri_heart_valve_23-2153.pdf - created

len (len@undisclosed.example.com) — 2026-01-12T01:17:07+00:00

azurity_pharma_23-1977.pdf - created

len (len@undisclosed.example.com) — 2026-01-12T01:12:04+00:00